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Introduction: The most commonly prescribed chemotherapy in ﬁrst 
line treatment of advanced NSCLC in UK patients (pts) is gemcitabine 
and carboplatin. However, for cancer centres(CC) where pts live in out-
lying areas, a safe, 3-weekly regimen is preferable. Docetaxel (D) was 
approved by NICE for ﬁrst line use with cis- (Pt) or carboplatin (C) in 
2005. There is no evidence that any combination has superior activity 
in ﬁrst line use but the ‘trade off’ of alopecia for less frequent hospital 
visits was explored in our practice.
Methods: Since 2004, all pts with a conﬁrmed diagnosis of NSCLC 
with advanced disease on CT staging, not suitable for a clinical trial 
and living >1 hour’s drive from the CC are offered ﬁrst line chemo-
therapy with D and Pt or C. Scalp cooling was offered from 2006. Data 
were entered on to a locally held Excel database.
Results: Between August 2004 and November 2006, 41 pts were 
treated. 33 were male and the age range was 47-77 (median 63) with all 
pts of ECOG performance status 0 or 1. The average number of cycles 
delivered was 4 (range 1-4). Stage of disease was IIIA (10pts), IIIB (9) 
and IV (22). Three pts had radiotherapy concomitantly, 19 sequentially 
and 2 prechemo. Response (WHO) was evaluable in 35 pts: CR 4, PR 
13, NC 9 and PD 9 for an overall disease control rate of 74%. Pts who 
elected to have scalp cooling did not develop alopecia >grade I in 90% 
of cases. Tolerance was good with no grade 4 toxicity. Survival data 
are being updated with increased patient numbers from this ongoing 
protocol.
Conclusion: Docetaxel with platinum is a safe, effective and conve-
nient regimen for ﬁrst line treatment in advanced NSCLC. Alopecia is 
preventable in pts who accept scalp cooling.
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Background: S-1, an oral ﬂuoropyrimidine derivative, has been shown 
to exhibit antitumor activity against chemotherapy-naïve NSCLC. It 
has been reported that S-1 has anti-angiogenic effect. The aim of this 
study was to evaluate the efﬁcacy and safety of S-1 for previously 
treated NSCLC and to assess the relation between the efﬁcacy of S-1 
and number of circulating endothelial cell (CEC).
Methods: Patients with histologically or cytologically conﬁrmed 
NSCLC, 20 to 80 years old, performance status (PS) 0-2, who under-
went platinum-based chemotherapy, were eligible. S-1 (80mg/m2/day) 
was administered twice a day on days 1-28 every 6 weeks for two to 
four courses. The primary endpoint was the response rate (RR). As-
suming that a RR of 20 % in eligible patients would indicate a potential 
usefulness of the regimen while a rate of 5 % would be the lower limit 
of interest and that alpha = 0.05 and beta = 0.20, the estimated number 
of required patients was 27 (Simon’s two-stage minimax design). Num-
ber of CEC was measured before treatment, on day 8, and 28. CEC was 
enumerated automatically as nucleated, CD146+, CD105+ and CD45- 
cells in 4 ml of peripheral blood.
Results: From June 2005 to May 2005, 27 patients (male/female: 21/6, 
median age: 62 years old, adeno/squamous/others: 17/7/3, PS 0/1/2: 
13/13/1, prior chemotherapy regimens 1/2/3: 7/13/7) were enrolled. 
Five partial responses were observed, for the RR of 19% (95% conﬁ-
dence interval: 12-26 %). The median survival time was 10.2 months 
and the median progression free survival (PFS) was 3.4 months. Grade 
3/4 leukopenia, neutropenia, and thrombocytopenia were observed in 
4, 7, and 4%, respectively. Grade 3/4 non-hematological toxicities were 
fatigue (7%), infection (7%), appetite loss (4%), and diarrhea (4%). Al-
though there was no relation between tumor response and CEC count, 
patients with < 50 CECs tended to have the longer PFS.
Conclusion: S-1 was active and tolerated for previously treated 
NSCLC and it was suggested that CEC count may correlate to the 
survival time.
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Background: Cisplatin is the cornerstone in advanced NSCLC, but 
the optimal sequencing of drugs and the role of non-cisplatin doublets 
remains to be deﬁned. The aim of this phase II trial was to evaluate the 
response rate of two different schedules of D and G and of a third arm 
of GC followed by D. 
Methods: Chemotherapy-naive stage IIIB (N3 or T4 pleural)/IV 
NSCLC patients (pts), ECOG performance 0-1, age 18-70 years 
received (Arm A) D (40mg/m2 days 1-8) and G (1200mg/m2 days 1-8) 
every 21 days, or (Arm B) D (50mg/m2; days 1-15) and G (1500mg/m2 
days 1-15) every 28 days, both for a maximum of 6 cycles, or (Arm C) 
G (1200mg/m2 days 1-8) and C (75 mg/m2 day 2) for 3 cycles followed, 
in case of stable disease (SD), partial (PR) or complete response (CR) 
by D (75 mg/m2 day 1) for 3 cycles, both every 21 days. 
Results: From July 2002 to May 2004, 128 pts were enrolled (41 in 
Arm A; 46 in Arm B; 41 in Arm C). Pts characteristics: overall median 
age 61 years, PS 0 in 52%, stage IIIB in 19% of pts. A total of 704 
cycles were given, 228 in arm A 208 in arm B and 268 in arm C respec-
tively, Fifty percent and 68.5% of patients completed the treatment in 
arm A and C whereas only the 30.3 % in arm B. The major cause of 
treatment withdrawn was progressive disease (20.3%; 30.3%, 16.7% in 
arm A, B, and C respectively). Treatment withdrawn for adverse events 
occurred in 7.4% 10.7% and 3.7% in arm A, B, and C, respectively. 
Toxicity (by cycles) according to WHO criteria was mainly hematolog-
ical, consisting of grade 3-4 neutropenia in 86 (17%) cycles (16/25/45) 
with less than 1% of febrile neutropenia and grade 3 thrombocytopenia 
in 19 (4%) cycles (6/2/11). Anemia g3-4 was present only in arm C in 
5 cycles (1%). Non-hematologic toxicity was generally mild across 
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the three arms: gastrointestinal g3-4 in 7 (1%) cycles, asthenia g3 in 
18 (4%) cycles, neurological g3 in 8 (2%) cycles and skin toxicity g3 
in 3 (<1%) cycles. Response rate as assessed after three cycles and at 
the end of treatment was: arm A=22%/24%, arm B=23%/12%, arm 
C=33%/28%. As March 2007, 129 patients died (44 arm A, 50 arm B 
and 35 arm C). The median survival is 10.7 mo, 8.9 mo and 14.6 mo in 
the arm A, B and C, respectively; HR: B vs A 1.17 (95% CI 0.77-1.78), 
C vs A 0.65 (95% CI0.77-1.78).The 1-yr progression free survival rate 
is:arm A 18%, arm B 8% and arm C 23%. 
Conclusion: All the arms are characterized by a mild toxicity, with 
a worse proﬁle for arm B. Even in the absence of a statistical signiﬁ-
cance, there is a trend of better efﬁcacy of the arm C versus A and 
B, which conﬁrm the role of platinum-based therapy in treatment of 
NSCLC.
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carboplatin in performance status 2 (PS2) patients with advanced 
(stage IIIB with pleural effusion or IV) non-small-cell lung cancer 
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Background: The optimal treatment of patients with advanced NSCLC 
and PS2 has not been resolved. A retrospective analysis of 99 patients 
with PS2 in CALGB 9730 (Lilenbaum, JCO 2005) demonstrated im-
proved survival associated with combination carboplatin-paclitaxel ver-
sus paclitaxel alone (median overall survival=4.7 vs. 2.4 mos., p=.019). 
Gemcitabine-carboplatin (GC) is an active doublet in advanced NSCLC 
and is at least as active as paclitaxel-carboplatin (PC) in PS2 patients 
(ECOG 1599, Tester ASCO 2004). A prospective validation of the 
activity of GC is needed, which is addressed by comparing GC versus 
gemcitabine (G) alone in this setting.
Methods: 161 chemonaïve patients with advanced NSCLC and PS2 
were randomly assigned to G 1250 mg/m2 alone on Days 1 and 8 or GC 
(G 1000 mg/m2 Days 1 and 8 followed by C AUC=5 on Day 1). Cycles 
were repeated every 21 days for 6 cycles or until disease progression or 
intolerable toxicity. The primary endpoint was median survival.
Characteristics/Results G alone GC combination
N enrolled 81 80
Median age (range) 75 (45-89) 73 (46-88)
Male:Female 57:43 54:46
N receiving drug 72 69
Mean cycles (range) 3.3 (1-6) 4.0 (1-6)
Relative dose intensity, % G:C 91:NA 72:90
G3 and 4 neutropenia, % pts G3:4 2.8:1.4 15.9:11.6
G3 and 4 thrombocytopenia, % pts G3:4 0:0 8.7:10.1
G3 and 4 febrile neutropenia, % pts G3:4 0:0 0:0
G3 and 4 anemia, % pts G3:4 1.4:0 7.2:0
N assessed for response 70 67
CR, % O O
PR, % 7.1 31.3
SD, % 35.7 31.3
PD, % 17.1 14.9
Unknown response, % 40.0 22.4
FACT-L trial outcome index (mean) 
Baseline 49.4 50.6
Cycle 1 49.27 50.15
Cycle 2 51.92 54.09
Cycle 3 51.08 55.27
Cycle 4 51.09 57.43
Cycle 5 50.11 59.53
Median survival following randomization (mos) 5.22 6.97
95% CI 3.61, 7.92 4.53, 10.81
Events:censored 45:24 44:23
Log-rank P value 0.489  
Median PFS following randomization (mos) 2.79 4.01
95% CI 1.84, 4.14 2.63, 6.14
Events:censored 52:17 48:19
Log-rank P value 0.424  
Cox regression model of survival Hazard ratio P value
GC vs G 0.84 0.415
Baseline LDH 1.70 0.017
Baseline weight 1.50 0.057
Conclusions: GC resulted in an improved response rate, overall 
survival, and progression-free survival time, but differences were not 
statistically signiﬁcant. As expected, G3-4 toxicities were greater with 
GC. Patients receiving GC had improved FACT-L quality-of-life scores 
at each cycle of treatment. Elevated baseline LDH and weight were 
associated with worsened outcome.
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Background: Pemetrexed (P), a multi-targeted antifolate, was syner-
gisitic with gemcitabine (G) in preclinical models. A Phase 1/2 trial was 
conducted to determine the optimal dose and sequence of the drugs and 
their effect on pts with advanced NSCLC.
Methods: In Phase 1, pts with advanced solid tumors were enrolled. 
In Phase 2, pts had Stage IIIB (with pleural effusion) or IV NSCLC, 
